DYNAVAX TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-14: Form 8-K; Period of report 2021-12-10; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-11-04: Form 8-K; Period of report 2021-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-10-21: Form 8-K; Period of report 2021-10-19; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-08-04: Form 8-K; Period of report 2021-08-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-14 | 8-K | 2021-12-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 10, 2021, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”) appointed Elaine Sun to serve as a Class I Director, effective immediately, to serve until the 2022 Annual Meeting of Stockholders, until her successor is duly elected and qualified, or until her earlier death, resignation or removal. | dvax-20211210.htm |
| 2021-11-04 | 8-K | 2021-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2021, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended September 30, 2021. | dvax-20211104.htm |
| 2021-10-21 | 8-K | 2021-10-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 19, 2021, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”) appointed Scott Myers to serve as a Class I Director and Chairman of the Board, effective immediately, to serve until the 2022 Annual Meeting of Stockholders, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. | d343945d8k.htm |
| 2021-08-04 | 8-K | 2021-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2021, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended June 30, 2021. | dvax-8k_20210804.htm |
| 2021-07-07 | 8-K | 2021-07-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 On July 1, 2021, Dynavax Technologies Corporation (the “Company”) entered into an agreement (the “Bio E Supply Agreement”) with Biological E. Limited (“Bio E”), for the commercial supply of the Company’s novel toll-like receptor 9 agonist, CpG 1018™ adjuvant, for use with Bio E’s subunit COVID-19 vaccine candidate, CORBEVAX™. | dvax-8k_20210701.htm |
| 2021-07-01 | 8-K | 2021-06-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 29, 2021, Dynavax Technologies Corporation (the “Company”) entered into an agreement (the “Clover Supply Agreement”) with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Hong Kong Inc. (collectively, “Clover”), for the commercial supply of the Company’s novel toll-like receptor 9 agonist, CpG 1018™ adjuvant, for use with Clover’s protein-based COVID-19 vaccine candidate, SCB-2019. | dvax-8k_20210629.htm |
| 2021-06-24 | 8-K | 2021-06-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 22, 2021, the Compensation Committee of the Board of Directors of Dynavax Technologies Corporation (the “Company”) approved an amendment to increase the reserve of shares of the Company’s common stock under the Dynavax Technologies Corporation 2021 Inducement Award Plan (the “2021 Inducement Award Plan”) from 1,500,000 to 3,250,000 shares of common stock (subject to customary adjustments in the event of a change in capital structure of the Company) to be used exclusively for grants of inducement awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as a material inducement within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules to each such individual’s entry into employment with the Company. | dvax-8k_20210622.htm |
| 2021-06-02 | 8-K | 2021-05-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 The 2021 Annual Meeting of Stockholders of Dynavax Technologies Corporation (the "Company") was held on May 28, 2021 in a virtual meeting format, pursuant to notice duly given (the “Annual Meeting”). 5.07 Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Board’s solicitations. | dvax-8k_20210528.htm |
| 2021-05-26 | 8-K | 2021-05-25 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 On May 25, 2021, Dynavax Technologies Corporation (the “Company”) issued an additional $25.5 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2026 (the “Additional Notes”) to the initial purchasers (the “Initial Purchasers”) named in its purchase agreement, dated May 10, 2021, with Goldman Sachs & Co. LLC, as representative of the initial purchasers named therein. 3.02 The information included in Item 2.03 of this Current Report on Form 8-K is incorporated into this Item 3.02 of this Current Report on Form 8-K by reference. | dvax-8k_20210525.htm |
| 2021-05-13 | 8-K | 2021-05-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 The information included in Item 8.01 of this Current Report on Form 8-K is incorporated into this Item 1.01 of this Current Report on Form 8-K by reference. 2.03 The information included in Item 8.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference. 3.02 The information included in Item 8.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 of this Current Report on Form 8-K by reference. 8.01 On May 10, 2021, Dynavax Technologies Corporation (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Goldman Sachs & Co. LLC, as representative of the initial purchasers named therein (the “Initial Purchasers”), relating to the sale (the “Note Offering”) by the Company of an aggregate of $200.0 million principal amount of its 2.50% Convertible Senior Notes due 2026 (the “Notes”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act. | d481425d8k.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended March 31, 2021. | dvax-8k_20210506.htm |
| 2021-05-05 | 8-K | 2021-05-03 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On May 3, 2021, Dynavax Technologies Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Agreement dated as of January 29, 2021 (the “Agreement”) with the Coalition for Epidemic Preparedness Innovations (“CEPI”). 2.03 The information included in Item 1.01 of this Current Report on Form 8-K with respect to the Loan Amount is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference. | dvax-8k_20210503.htm |
| 2021-04-06 | 8-K | 2021-04-06 | 8.01 Other Events | 8.01 On April 6, 2021, Dynavax Technologies Corporation (the “Company”) announced that its collaborator, Valneva SE (“Valneva”), reported initial clinical trial results for Part A of its Phase 1/2 inactivated COVID-19 vaccine candidate, VLA2001, using the Company’s proprietary CpG 1018™ adjuvant in 153 adults aged 18 to 55 years. | dvax-8k_20210406.htm |
| 2021-02-25 | 8-K | 2021-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2021, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter and year ended December 31, 2020. | dvax-8k_20210225.htm |
| 2021-02-19 | 8-K | 2021-02-19 | 8.01 Other Events | 8.01 On February 19, 2021, Dynavax Technologies Corporation issued a press release entitled, “Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine,” a copy of which is attached hereto as exhibit 99.1 and incorporated herein by reference. | dvax-8k_20210219.htm |
| 2021-02-01 | 8-K | 2021-01-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information included in Item 1.01 of this Current Report on Form 8-K with respect to the Loan Amount is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference. 8.01 On February 1, 2021 the Company announced that it is supporting Clover Biopharmaceuticals, Inc. (“Clover”) in its efforts to initiate a global Phase 2/3 efficacy trial (the “Clover Trial”) with Clover’s S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. | dvax-8k_20210129.htm |
| 2021-01-21 | 8-K | 2021-01-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 19, 2021, Dynavax Technologies Corporation (the “Company”) appointed Kelly MacDonald as its Senior Vice President, Chief Financial Officer, and Principal Financial Officer, effective upon her start date, which is expected to be March 1, 2021. | dvax-8k_20210119.htm |
| 2021-01-12 | 8-K | 2021-01-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 9, 2021, Dynavax Technologies Corporation (the “Company”) adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (the “Inducement Plan”), pursuant to which the Company reserved 1,500,000 shares of its common stock for issuance under the Inducement Plan to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Nasdaq Listing Rule 5635(c)(4). | dvax-8k_20210109.htm |
| 2021-01-07 | 8-K | 2021-01-07 | 8.01 Other Events | 8.01 On January 7, 2021, Dynavax Technologies Corporation (the “Company”) announced final immunogenicity and interim safety results from an ongoing clinical trial evaluating HEPLISAV-B in patients undergoing hemodialysis. | dvax-8k_20210107.htm |